Alphatec (NASDAQ:ATEC) EVP Sells $39,193.70 in Stock

Key Points

• David Sponsel, EVP of Alphatec, sold 2,555 shares of stock for $39,193.70, reducing his ownership by 0.48% while retaining 531,861 shares valued at over $8 million.
• Alphatec reported a 27.5% year-over-year increase in revenue to $185.54 million for the recent quarter, beating analysts' expectations and posting $0.02 earnings per share.
• Analysts are optimistic about Alphatec, with multiple buy ratings issued and price targets ranging from $18.00 to $22.00, indicating potential growth in the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) EVP David Sponsel sold 2,555 shares of the stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $15.34, for a total value of $39,193.70. Following the transaction, the executive vice president owned 531,861 shares in the company, valued at $8,158,747.74. This represents a 0.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

David Sponsel also recently made the following trade(s):

• On Thursday, September 18th, David Sponsel sold 137,445 shares of Alphatec stock. The shares were sold at an average price of $15.09, for a total value of $2,074,045.05.

Alphatec Price Performance

Shares of Alphatec stock traded up $0.06 during mid-day trading on Monday, reaching $15.60. 1,373,090 shares of the stock traded hands, compared to its average volume of 1,936,744. The business has a 50-day moving average of $14.32 and a 200 day moving average of $12.24. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $16.70. The stock has a market capitalization of $2.31 billion, a PE ratio of -13.81 and a beta of 1.02. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter in the prior year, the firm earned ($0.29) earnings per share. The business's revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on ATEC shares. Barclays reissued an "overweight" rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a report on Monday, August 4th. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target for the company in a report on Monday, June 16th. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a report on Sunday, September 7th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 1st. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $18.50.

Institutional Investors Weigh In On Alphatec

Several hedge funds and other institutional investors have recently made changes to their positions in ATEC. GAMMA Investing LLC increased its stake in Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after acquiring an additional 2,306 shares during the last quarter. Osterweis Capital Management Inc. acquired a new stake in Alphatec during the second quarter worth $37,000. Larson Financial Group LLC acquired a new stake in Alphatec during the first quarter worth $54,000. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after acquiring an additional 1,045 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in Alphatec during the fourth quarter worth $76,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.